

# Biotinylated Anti-Murine EGF Antibody

Catalog # ABG10067

## Product Information

---

|                    |            |
|--------------------|------------|
| <b>Application</b> | WB, E      |
| <b>Reactivity</b>  | Mouse      |
| <b>Host</b>        | Goat       |
| <b>Clonality</b>   | Polyclonal |

## Additional Information

---

|                       |                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Preparation</b>    | Produced from sera of goats pre-immunized with highly pure (>98%) recombinant mEGF. Anti-Murine EGF specific antibody was purified by affinity chromatography and then biotinylated.                                                                                                                                                              |
| <b>WesternBlot</b>    | To detect mEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant mEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.                                                                  |
| <b>Sandwich</b>       | To detect mEGF by sandwich ELISA (using 100 µl/well antibody solution) a concentration of 0.25 – 1.0 µg/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with BioGems's Polyclonal Anti-Murine EGF (61-063P) as a capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant mEGF. |
| <b>Direct</b>         | To detect mEGF by direct ELISA (using 100 µl/well antibody solution) a concentration of 0.25 – 1.0 µg/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2 – 0.4 ng/well of recombinant mEGF.                                          |
| <b>Formulation</b>    | A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.                                                                                                                                                                                                                                                                            |
| <b>Reconstitution</b> | Centrifuge vial prior to opening. Reconstitute in sterile PBS containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.                                                                                                                                                                                                                            |
| <b>Storage</b>        | -20°C                                                                                                                                                                                                                                                                                                                                             |
| <b>Precautions</b>    | Biotinylated Anti-Murine EGF Antibody is for research use only and not for use in diagnostic or therapeutic procedures.                                                                                                                                                                                                                           |

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.